Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Trial Profile

Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Asparaginase (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Idarubicin (Primary) ; Methotrexate (Primary) ; Folinic acid
  • Indications Blastic plasmacytoid dendritic cell neoplasm
  • Focus Therapeutic Use
  • Acronyms LpDessai
  • Most Recent Events

    • 10 Dec 2018 Planned initiation date changed from 1 Sep 2018 to 1 Jan 2019.
    • 06 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
    • 01 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top